E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Immune thrombocytopenic purpura (ITP). |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess in both treatment arms the rate of splenectomy at 1.5 years. |
|
E.2.2 | Secondary objectives of the trial |
1. Response rates. 2. Relapse rate and duration of response. 3. Mortality rate. 4. Complications` rate: bleeding, infection and thromboembolic events. 5. Cost-effectiveness analysis. 6. Consumption of corticosteriods and IVIG in both arms. 7. Immune-reconstruction at 1.5 years. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. ITP with platelet count <30 x 109 /l or 30-50 x 109 /l if a higher platelet count is considered necessary because of any of the following: a. Concomitant medical illness predisposing to bleeding (gastric ulcer, bleeding diathesis, previous history of bleeding). b. Concomitant medical condition requiring aspirin and/or clopidogrel intake or anticoagulation. c. Persistent bleeding manifestations despite platelets > 30 x 109 /l. d. Other patient related factors necessitating higher platelet count as occupation, hobby, psychological intolerability. e. Age >75 years.
2. Previous treatment with corticosteroids for a minimum duration of 2 weeks as recommended by the protocol (prednisone or prednisolone 1-2 mg/kg/day) with either no response (i.e. failed to achieve an initial increase in Platelet count >30 x 109 /l) or relapse (Platelet count falls to < 30 x 109 /l) during the dose tapering period or after discontinuation of corticosteroids.
3. Subject is >18 years.
4. Subject has signed and dated written informed consent.
5. Subject is able to understand and comply with protocol requirements and instructions, and intends to complete the study as planned.
6. Females in child-bearing age should accept to use of contraceptive means for at least 6 months following the administration of the study drugs. |
|
E.4 | Principal exclusion criteria |
1. Previous splenectomy, chemotherapy, treatment with anti-D Ig, rituximab, or immune-suppressive treatments other than corticosteroids, Dapsone or Danazol.
2. Underlying malignancy or previous history of malignancy in the past 5 years (except skin carcinoma).
3. Pregnancy and lactation.
4. Not willing to participate in the study.
5. Expected survival of < 2 years.
6. Known intolerance to murine antibodies.
7. Females in child-bearing age not willing to use contraception for 6 months.
8. HIV/AIDS-, Hepatitis -B virus antigen positive- or Hepatitis -C virus antibodies positive- patients.
9. Patients with Systemic Lupus Erythematosus (SLE) (> 4 of the American College of Rheumatology Criteria) (Tan et al, 1982;Hochberg, 1997).
10. Patients currently involved in another clinical trial with evaluation of drug treatment.
11. Bacterial infections, viral infections, fungal infections, myco-bacterial infections (excluding ungeal fungal infections) or other evolutive infections or any other infections episode requiring hospitalisation or treatment with an antibiotics 4 weeks before selection for IV route or within 2 weeks before selection for oral route.
12. History of soft tissue, bone or joint infections (fascitis, abscess, osteomyelitis, septic arthritis) during the last year prior to inclusion in the study.
13. Medical history of relapsing or chronic severe infectious diseases or any other underlying pathology predisposing to serious infections.
14. Known Primary or secondary immune deficiency syndromes.
15. Administration of a living vaccine within 4 weeks preceding the inclusion in the study.
16. History of soft tissue, bone or joint infections (fascitis, abscess, osteomyelitis, septic arthritis) during the last year prior to inclusion in the study.
17. Previous treatment with inhibitors of leucocytes transmigration (e.g.: Tysabri®).
18. Known intolerance to human monoclonal antibodies.
19. Known severe chronic pulmonary obstructive Disease (FEV < 50% or functional dyspnoea grade 3).
20. Known congestive heart failure NYHA (New York Heart Association classification of heart failure) class III and IV.
21. Recent episode (<6 months) of acute coronary syndrome. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess in both treatment arms the rate of splenectomy at 1.5 years. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.6.13.1 | Other scope of the trial description |
1- Response rates 2- Relapse rates and |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Primary end point: A splenectomy during the follow-up period after randomisation.
Secondary endpoints: 1-Death during follow-up period 2-Relapse defined as platelet count <30 x 109/l following an initial response and duration of response. 3- Episodes of bleeding, infection and thromboembolic events. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 15 |